Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Reduced by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 7.5% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 33,377 shares of the specialty pharmaceutical company’s stock after selling 2,717 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Jazz Pharmaceuticals were worth $3,719,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. EverSource Wealth Advisors LLC increased its position in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares during the period. GAMMA Investing LLC increased its holdings in shares of Jazz Pharmaceuticals by 65.5% during the second quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 116 shares during the period. Arizona State Retirement System raised its stake in shares of Jazz Pharmaceuticals by 0.8% during the second quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after purchasing an additional 130 shares in the last quarter. Cardinal Capital Management raised its stake in shares of Jazz Pharmaceuticals by 1.9% during the second quarter. Cardinal Capital Management now owns 12,068 shares of the specialty pharmaceutical company’s stock valued at $1,288,000 after purchasing an additional 227 shares in the last quarter. Finally, Waterfront Wealth Inc. lifted its holdings in Jazz Pharmaceuticals by 2.5% in the second quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company’s stock worth $1,004,000 after purchasing an additional 230 shares during the period. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Trading Up 4.9 %

Jazz Pharmaceuticals stock opened at $125.10 on Friday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market capitalization of $7.56 billion, a price-to-earnings ratio of 17.62, a P/E/G ratio of 0.98 and a beta of 0.57. The company has a 50 day moving average price of $112.92 and a 200 day moving average price of $110.52.

Insider Transactions at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 6,110 shares of company stock valued at $720,160 over the last quarter. Company insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on JAZZ. TD Cowen dropped their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research report on Thursday, November 7th. Robert W. Baird boosted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday. JPMorgan Chase & Co. increased their price target on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. Royal Bank of Canada boosted their price objective on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 23rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday. Three investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.33.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.